Provided by Tiger Trade Technology Pte. Ltd.

CorMedix Inc.

12.02
+0.10000.84%
Post-market: 12.00-0.0200-0.17%19:52 EST
Volume:3.69M
Turnover:44.20M
Market Cap:947.04M
PE:5.34
High:12.08
Open:11.86
Low:11.75
Close:11.92
52wk High:17.43
52wk Low:5.60
Shares:78.79M
Float Shares:73.69M
Volume Ratio:1.32
T/O Rate:5.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.25
EPS(LYR):-0.3046
ROE:75.08%
ROA:15.68%
PB:2.53
PE(LYR):-39.47

Loading ...

Company Profile

Company Name:
CorMedix Inc.
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
65
Office Location:
300 Connell Drive,Suite 4200,Berkeley Heights,New Jersey,United States
Zip Code:
07922
Fax:
908 375 8272
Introduction:
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Directors

Name
Position
Joseph Todisco
Director and Chief Executive Officer
Myron Kaplan
Director and Chairman of the Board
Alan W. Dunton
Director
Greg Duncan
Director
Janet M. Dillione
Director
Robert Stewart
Director
Steven W. Lefkowitz
Director

Shareholders

Name
Position
Joseph Todisco
Director and Chief Executive Officer
Susan Blum
Chief Financial Officer
Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Elizabeth Hurlburt
Executive Vice President and Chief Clinical Strategy and Operations Officer
Erin Mistry
Executive Vice President and Chief Commercial Officer
Matthew David
Executive Vice President and Chief Business Officer